Patients should not require concurrent therapeutic doses of steroids (>  mg of prednisone/day or equivalent) unless they need them for the indications; steroids should be discontinued for  days before starting protocol treatment
Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses greater than . to  mg/day prednisone or equivalent) must be discontinued at least  weeks before study drug administration.
In addition to neurosurgery to treat CNS metastases, adjuvant radiation after the resection of CNS metastasis is allowed; immunosuppressive doses of systemic steroids (doses >  mg/day prednisone or equivalent) must be discontinued at least  days before study drug administration
Patients who are on high dose steroid (e.g. >  mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g. infliximab)
Not currently requiring systemic corticosteroid therapy ( mg or less of prednisone or equivalent doses of other systemic steroids are allowed) or any other immune suppressive medications
Patients who are on high-dose steroids (doses >  mg/day of prednisone or equivalent) or immune suppression medications; NOTE: Patients on high-dose steroids (doses >  mg/day of prednisone or equivalent) or immune suppression medications are eligible provided these drugs are discontinued at least  days prior to starting on the study drugs
Able to be off of corticosteroids ( mg or less of prednisone or equivalent doses of other systemic steroids are allowed) and any other immune suppressive medications beginning on day -
Patients who are on steroids (>  mg/day or equivalent) or immune suppression medications
Patients who are on high dose steroid (equivalent of prednisone more than  mg a day) or immune suppression medications
Patients who are on high dose steroid (>  mg daily of prednisone or equivalent) or immune suppression medications; Note: patients on high-dose steroids (doses > mg/day of prednisone or equivalent) or immune suppression medications are eligible provided these drugs are discontinued at least  days prior to starting on the study drugs
Patients who are on high dose steroid (e.g. >  mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g. infliximab)
Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses >  mg/day prednisone or equivalent) must be discontinued at least  weeks before study drug administration
Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses >  mg/day prednisone or equivalent) must be discontinued at least  weeks before study drug administration
Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses >  mg/day prednisone or equivalent) must be discontinued at least  weeks before study drug administration
Patients who are on high dose steroid (i.e. prednisone or equivalent more than  mg a day) or immune suppression medications
Patients who are on high-dose steroids (doses >  mg/day of prednisone or equivalent) or immune suppression medications; Note: patients on high-dose steroids (doses > mg/day of prednisone or equivalent) or immune suppression medications are eligible provided these drugs are discontinued at least  days prior to starting on the study drugs
Immunosuppressive doses of systemic medication, such as steroids or absorbed topical steroids (doses >  mg/day prednisone or equivalent) must be discontinued at least  days prior to nivolumab administration
In addition to neurosurgery to treat CNS metastases, adjuvant radiation after the resection of CNS metastasis is allowed. Immunosuppressive doses of systemic steroids (doses ?  mg/day prednisone or equivalent) must be discontinued at least  days before study drug administration.
Immune suppression
Patients who are on high-dose steroids (doses >  mg/day of prednisone or equivalent) or immune suppression medications; Note: patients on high-dose steroids (doses > mg/day of prednisone or equivalent) or immune suppression medications are eligible provided these drugs are discontinued at least  days prior to starting on the study drugs